CA3190511A1 - Use of a dhodh inhibitor compound in combination cancer therapy - Google Patents

Use of a dhodh inhibitor compound in combination cancer therapy

Info

Publication number
CA3190511A1
CA3190511A1 CA3190511A CA3190511A CA3190511A1 CA 3190511 A1 CA3190511 A1 CA 3190511A1 CA 3190511 A CA3190511 A CA 3190511A CA 3190511 A CA3190511 A CA 3190511A CA 3190511 A1 CA3190511 A1 CA 3190511A1
Authority
CA
Canada
Prior art keywords
lymphoma
compound
pharmaceutically acceptable
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3190511A
Other languages
English (en)
French (fr)
Inventor
John COCO
Brandon NICOLAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CA3190511A1 publication Critical patent/CA3190511A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3190511A 2020-08-27 2021-08-26 Use of a dhodh inhibitor compound in combination cancer therapy Pending CA3190511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070984P 2020-08-27 2020-08-27
US63/070,984 2020-08-27
PCT/US2021/047778 WO2022047051A1 (en) 2020-08-27 2021-08-26 Use of a dhodh inhibitor compound in combination cancer therapy

Publications (1)

Publication Number Publication Date
CA3190511A1 true CA3190511A1 (en) 2022-03-03

Family

ID=78000775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3190511A Pending CA3190511A1 (en) 2020-08-27 2021-08-26 Use of a dhodh inhibitor compound in combination cancer therapy

Country Status (9)

Country Link
US (1) US20230285365A1 (https=)
EP (1) EP4203950B1 (https=)
JP (1) JP7734742B2 (https=)
KR (1) KR20230078997A (https=)
CN (1) CN116847874A (https=)
BR (1) BR112023003493A2 (https=)
CA (1) CA3190511A1 (https=)
ES (1) ES3063941T3 (https=)
WO (1) WO2022047051A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
JOP20210147A1 (ar) * 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
HRP20211462T1 (hr) * 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
WO2020109625A1 (en) * 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
JOP20210147A1 (ar) 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Also Published As

Publication number Publication date
CN116847874A (zh) 2023-10-03
US20230285365A1 (en) 2023-09-14
WO2022047051A1 (en) 2022-03-03
JP7734742B2 (ja) 2025-09-05
KR20230078997A (ko) 2023-06-05
EP4203950C0 (en) 2026-02-18
ES3063941T3 (en) 2026-04-21
EP4203950A1 (en) 2023-07-05
BR112023003493A2 (pt) 2023-04-11
JP2023540206A (ja) 2023-09-22
EP4203950B1 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
EP4203950B1 (en) Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma
US7678391B2 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6573292B1 (en) Methods and compositions for the treatment of chronic lymphocytic leukemia
US20180028444A1 (en) Compositions and methods of tumor treatment utilizing nanoparticles
WO2010081817A1 (en) Method for treating colorectal cancer
WO2022218956A1 (en) Combination comprising ribociclib and amcenestrant
CN114423429A (zh) 卢比克替定治疗恶性间皮瘤
WO2021262881A1 (en) Use of a dhodh inhibitor compound in combination cancer therapy
TW201817425A (zh) 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法
TW202038932A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
US20150071919A1 (en) Cancer therapy
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
US20250186438A1 (en) Treatment of clear cell renal cell carcinoma
TW202038931A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
EA049299B1 (ru) Применение соединения-ингибитора на основе dhodh в комбинированной терапии рака
NZ551637A (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
AU2024304092A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
CA3089630C (en) Combination therapy for the treatment of mastocytosis
EP4561577A1 (en) Cancer combination therapy including a flt3-inhibitor
WO2025113523A1 (zh) 熊果酸和多靶点酪氨酸激酶受体抑制剂的药物组合
TW202315615A (zh) Pi3k抑制劑與btk抑制劑在製備治療淋巴瘤的藥物中的用途
CN111419853A (zh) 一种治疗乳腺癌的葫芦素与依鲁替尼组合物
EA052412B1 (ru) Комбинированная терапия для лечения мастоцитоза

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240812

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240812

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240812

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250818

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250818

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250819

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250829

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251028

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251028

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251028

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251028

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251103